Recombinant T cell receptor ligand treats experimental stroke. - Wikidata - awgldk - TriplyDB

Recombinant T cell receptor ligand treats experimental stroke.

Recombinant T cell receptor ligand treats experimental stroke.

http://www.wikidata.org/entity/Q37246578

about

Neuroimmune basis of methamphetamine toxicity Partial MHC/neuroantigen peptide constructs: a potential neuroimmune-based treatment for methamphetamine addiction The immunology of stroke: from mechanisms to translation How and why do T cells and their derived cytokines affect the injured and healthy brain?Targeting microglial activation in stroke therapy: pharmacological tools and gender effects.Leukocyte recruitment and ischemic brain injury.Novel humanized recombinant T cell receptor ligands protect the female brain after experimental stroke Recombinant T cell receptor ligand treatment improves neurological outcome in the presence of tissue plasminogen activator in experimental ischemic stroke.Targeting immune co-stimulatory effects of PD-L1 and PD-L2 might represent an effective therapeutic strategy in stroke.Antigen-specific immune reactions to ischemic stroke.Different immunological mechanisms govern protection from experimental stroke in young and older mice with recombinant TCR ligand therapy.Characterization of human platelet binding of recombinant T cell receptor ligand.Soluble MOG35-55/I-A(b) dimers ameliorate experimental autoimmune encephalomyelitis by reducing encephalitogenic T cells 2014 Thomas Willis Award Lecture: sex, stroke, and innovation Preclinical evaluation of recombinant T cell receptor ligand RTL1000 as a therapeutic agent in ischemic stroke Therapy with recombinant T-cell receptor ligand reduces infarct size and infiltrating inflammatory cells in brain after middle cerebral artery occlusion in mice Recombinant T-cell receptor ligand RTL1000 limits inflammation and decreases infarct size after experimental ischemic stroke in middle-aged mice Estradiol and G1 reduce infarct size and improve immunosuppression after experimental stroke.Recombinant T cell receptor ligands improve outcome after experimental cerebral ischemia.Treatment with AMD3100 attenuates the microglial response and improves outcome after experimental stroke Myelin specific cells infiltrate MCAO lesions and exacerbate stroke severity.A novel mouse model of thromboembolic stroke.Levetiracetam Prevents Perforin Mediated Neuronal Injury Induced by Acute Cerebral Ischemia Reperfusion.Importance of T lymphocytes in brain injury, immunodeficiency, and recovery after cerebral ischemia.A novel hypothesis: regulatory B lymphocytes shape outcome from experimental stroke.Insulin-Like Growth Factor (IGF)-I Modulates Endothelial Blood-Brain Barrier Function in Ischemic Middle-Aged Female Rats.Method parameters' impact on mortality and variability in mouse stroke experiments: a meta-analysis.Partial MHC Constructs Treat Thromboembolic Ischemic Stroke Characterized by Early Immune Expansion Substance use disorders: psychoneuroimmunological mechanisms and new targets for therapy.A novel regulatory pathway for autoimmune disease: binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerance Sex differences in the immune response to experimental stroke: Implications for translational research.A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke Peptide-MHC-based nanovaccines for the treatment of autoimmunity: a "one size fits all" approach?Are you in or out? Leukocyte, ion, and neurotransmitter permeability across the epileptic blood-brain barrier.The immunology of acute stroke.Post-ischemic inflammation in the brain.Effects of Neuroinflammation on Neural Stem Cells.DRα1-MOG-35-55 treatment reduces lesion volumes and improves neurological deficits after traumatic brain injury.Upregulation of CD74 and its potential association with disease severity in subjects with ischemic stroke.Partial MHC class II constructs as novel immunomodulatory therapy for stroke.

P2860

Q28247084-5E0B5EC2-4909-4B77-8031-DE9B82896EA0 Q28486981-1A482559-3169-47AD-B57D-E609368C0460 Q29620066-137831AC-14F7-4A58-86D9-D2EA1FFE0F3B Q30252510-35672C19-50B8-4107-B475-BE0333C7A84D Q33824991-E2B4B326-96F8-485A-8FE6-1A43CE9695DB Q33886526-FEA46291-B2C4-4034-A120-83D0F7FA909A Q34001070-2A38AB4F-4782-4EE4-A249-87EB3172F8A7 Q34017153-67355080-E656-491F-85A6-94435F4B2663 Q34024724-CFBC7402-872D-4A4D-8AB8-8104A3D019ED Q34171339-28501AB5-5918-48C2-9041-D8C5F04ABFBE Q34242088-D7B0CFF0-5AE8-4EF0-BE50-7C08FF2BC12D Q34350992-5A4F4D94-1584-44C5-8FA0-A92F40C66E14 Q34450848-7E0F6BBB-932E-45F6-9E38-36A91BC39C4E Q34577247-F67CD609-E134-40A7-A3B9-F7ECF23B528D Q34982895-7FD53177-EDAB-49D9-9EF9-5AD7709C62E8 Q35036755-36864CC8-C0FC-4BD5-9A92-CACEE30FD054 Q35071226-4B64F286-F91B-4287-A977-A429FE043F10 Q35125543-CB6EC4A2-80C9-4371-948F-231215789340 Q35234869-230AF6F5-DFEC-42C7-B335-CF651D1569B1 Q35604382-769942B7-E92E-40D0-AF2C-235C262F9BDD Q35722702-2C200C6F-0C4F-4ABE-AA54-197B7A0006A3 Q35781185-855FC72D-F7D0-4373-83CA-6582957C15C9 Q35802649-C651D146-B2ED-4779-9FDD-05AD43662B0F Q35866882-922BA1B9-421F-462A-9C8A-FFDDAF7E72C6 Q36408695-AC93609E-B7D1-439C-A233-D013F1648257 Q36431776-A813E643-F4CA-46A5-882B-62E15EAE95DE Q36579398-0231E467-1170-4D77-B81A-1D4F5080DC6F Q36790648-E30AA8C9-70B2-4CBE-B746-0E3DE52A76AD Q37052393-BD66DD36-F1E7-4E5A-A9D2-82B226FE4AC3 Q37212157-D4B0537A-522B-4253-91C5-88482B22CF03 Q37432327-C598E5CC-C125-4DCD-99C1-7640F9077CCD Q37684577-F8B1DD8C-59BA-440C-9B9B-324DFCC5E0AD Q37866131-82639469-12BB-4393-B7E8-4B74DB0DF902 Q38011831-36853D2A-43C1-4087-9233-35EE0207A0FC Q38016069-E4825DC5-9BD9-4B2F-97AC-6A066B2C2585 Q38029598-0A89157F-D741-4268-BA92-C8382982060B Q38667253-8617C7DE-AD6E-4993-9F86-A6BB2C86C85F Q38743804-EE8B4392-BAC9-4212-AFF0-31A134B909C2 Q38791052-F351F359-C02A-45EC-BEC7-477710E3EDB7 Q38988985-5E6113D2-99B6-4D26-A82E-114E09F508C6

P2860

Recombinant T cell receptor ligand treats experimental stroke.

http://www.wikidata.org/entity/Q37246578

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 May 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Recombinant T cell receptor ligand treats experimental stroke.

@en

Recombinant T cell receptor ligand treats experimental stroke.

@nl

type

label

Recombinant T cell receptor ligand treats experimental stroke.

@en

Recombinant T cell receptor ligand treats experimental stroke.

@nl

prefLabel

Recombinant T cell receptor ligand treats experimental stroke.

@en

Recombinant T cell receptor ligand treats experimental stroke.

@nl

P1433

Q37246578-4CBD440A-23B4-45AA-88D4-EAF7E5702EB3

P1476

Q37246578-3B22A9A1-8552-45B7-B89F-AAF9F21110C3

P2093

Q37246578-13B095FA-5AD5-46C0-8957-21DAD8EEC006

Q37246578-172CB10E-4D1C-4637-B3D3-5BDD69BE57BD

Q37246578-3E3A9DB7-E7B5-4C4B-AAD9-FC83B5397534

Q37246578-74C72200-CBD9-4ED2-8245-CEC265AF87D9

Q37246578-7619F2F5-484A-4926-B911-A00999DAC5EE

Q37246578-8694D71B-3248-488A-83E0-494DD595292E

Q37246578-D160303B-3039-4DF3-AA68-B53EDA7C0623

Q37246578-EA709C72-5D39-40E6-9A24-84D51C24BC34

P2860

Q37246578-03FC1E3C-B661-4DF7-854B-1F8EC5DBEEBF

Q37246578-05DC8A6D-8689-4100-AB04-90E9E8171B50

Q37246578-12901C33-5D2D-4AEF-A9EA-8FE1C09BD9BE

Q37246578-27760EE6-1A85-4A59-87DF-C2195B055D04

Q37246578-29B9C8E2-B644-4801-A8CD-4FB9D2F718BA

Q37246578-3AFAD63B-47B9-4ED3-9C1C-CB0E340ED88C

Q37246578-47546D77-CE9F-419D-92C7-EED5F6405216

Q37246578-4E53285D-240B-4623-86F0-D9777F19BCE9

Q37246578-58E8E5E9-6EF3-4AAA-B3CE-8075B5E266D2

Q37246578-59996D14-660B-462D-A1DB-5BE60B6AC66A

P304

Q37246578-8DEFBC67-DE3E-4067-963F-A4F108010920

P31

Q37246578-57B3A0DE-AD91-4BB1-AF02-309B4F324188

P356

Q37246578-40C80751-37F7-4390-ADCA-376158916C7B

P407

Q37246578-F0B6ACBD-7B28-43F8-929D-EA32C0FAAB6C

P433

Q37246578-091D065B-0B02-46C6-B142-D378679C27BF

P478

Q37246578-753B5889-8460-4843-A477-D43CBDBB46CC

P577

Q37246578-9C125EEA-4018-4011-BB74-6DCE0D72CF48

P698

Q37246578-AF8A1331-5E89-41D1-94AF-3C757A486791

P932

Q37246578-10CB2F1E-FC12-4AEA-B519-E57F8DF5013F

P356

STROKEAHA.108.543991

P1433

P1476

Recombinant T cell receptor ligand treats experimental stroke.

@en

P2093

Arthur A Vandenbark

http://www.w3.org/2001/XMLSchema#string

Bing Zhang

http://www.w3.org/2001/XMLSchema#string

Gregory G Burrows

http://www.w3.org/2001/XMLSchema#string

Halina Offner

http://www.w3.org/2001/XMLSchema#string

Marjorie R Grafe

http://www.w3.org/2001/XMLSchema#string

Patricia D Hurn

http://www.w3.org/2001/XMLSchema#string

Sandhya Subramanian

http://www.w3.org/2001/XMLSchema#string

Yasuharu Kosaka

http://www.w3.org/2001/XMLSchema#string

P2860

Alternate interactions define the binding of peptides to the MHC molecule IA(b).

Two-domain MHC class II molecules form stable complexes with myelin basic protein 69-89 peptide that detect and inhibit rat encephalitogenic T cells and treat experimental autoimmune encephalomyelitis

Nasal vaccination with myelin oligodendrocyte glycoprotein reduces stroke size by inducing IL-10-producing CD4+ T cells.

Rationally designed mutations convert complexes of human recombinant T cell receptor ligands into monomers that retain biological activity.

Identification of the target self-antigens in reperfusion injury.

Central nervous system injury-induced immune deficiency syndrome.

MHC class II derived recombinant T cell receptor ligands protect DBA/1LacJ mice from collagen-induced arthritis.

Inflammation following stroke.

Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation.

An inverse relationship between T cell receptor affinity and antigen dose during CD4(+) T cell responses in vivo and in vitro

P304

2539-2545

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/STROKEAHA.108.543991

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19443805

http://www.w3.org/2001/XMLSchema#string

P932

2704258

http://www.w3.org/2001/XMLSchema#string